

FIGURE 5. Overnight platelet counts to haematocrit ratios decreased in patients with obstructive sleep apnoea (OSA). Platelet counts were normalised to the patient's haematocrit to control for differences in hydration status. Ratios of platelet count to haematocrit were obtained at 21:00 h and 06:00 h in a) six sleep controls and in b) 31 OSA patients, both without CPAP treatment. In the sleep controls, the ratios did not change between time points. In the OSA patients, the ratio exhibited significant changes between time points. Data are presented as mean \pm SD. NS: nonsignificant. **: $p < 0.01$.

Relationship of AHI and groups 1–3 of VWFm patterns in OSA patients

AHI is an excellent means of showing OSA severity, here we have used it to categorise three groups: moderate ($15 \leq \text{AHI} < 30$),

severe ($30 \leq \text{AHI} < 60$), and extremely severe ($\text{AHI} \geq 60$). As shown in table 3, OSA patients with group 1 and 2 consisted of those with variable AHI levels. Notably, none of the OSA patients within group 3 had an AHI $15 \sim < 30$, and they uniformly

TABLE 2 Characteristics and different parameter between 21:00 h and 06:00 h of patients with obstructive sleep apnoea (OSA) in groups 1–3

	Group			Overall p-value
	1	2	3	
Sex M/F	28/1	18/0	9/2	NS
Blood type				NS
A	7	4	7	
B	4	4	0	
O	14	7	4	
AB	4	3	0	
Age yrs	46.0 \pm 9.6	42.9 \pm 9.7	44.2 \pm 11.3	NS
AHI	43.1 \pm 20.0	51.4 \pm 19.6	68.7 \pm 22.6	<0.05*
ODI3%	35.7 \pm 18.2	44.1 \pm 19.3	53.2 \pm 21.5	<0.01 [#]
Differences in time intervals 06:00 and 21:00 h				
VWF:Ag %	2.1 \pm 34.8	10.8 \pm 22.0	-28.1 \pm 40.6	<0.05 [†]
LMW ratio %	-0.27 \pm 5.24	-4.46 \pm 8.69	16.69 \pm 16.92	<0.01 [†]
ADAMTS13:AC %	4.4 \pm 13.1	-8.5 \pm 25.9	2.4 \pm 21.4	<0.05*
Plt/Ht $\times 10^9 \cdot L^{-1} \cdot \%^{-1}$	-0.045 \pm 0.036 (n=15)	-0.034 \pm 0.038 (n=10)	-0.043 \pm 0.029 (n=6)	NS

Data are presented as n or mean \pm SD, unless otherwise stated. M: males; F: females; AHI: apnoea/hypopnoea index, ODI3%: oxygen desaturation index $\geq 3\%$; VWF:Ag: von Willebrand factor antigen; LMW ratio: the ratio of low molecular weight-VWFMs to total VWFMs; ADAMTS13:AC: a disintegrin-like, metalloproteinase, and thrombospondin type 1 motifs 13 activity; Plt/Ht: platelet count to haematocrit ratio. NS: not significant. *: $p < 0.05$ between groups 1, 2 and 3; [#]: $p < 0.01$ between groups 1 and 3; [†]: $p < 0.01$ between groups 1, 2 and 3; ^{*}: $p < 0.05$ between group 1 and 2.

TABLE 3 Characteristics and thrombotic parameters of patients classified with apnoea/hypopnoea index (AHI)

	15 ≤ AHI < 30	30 ≤ AHI < 60	AHI ≥ 60	Overall p-value
Patients n	15	22	21	
Sex M/F	15/0	21/1	19/2	NS
Age yr	43.7 ± 12.0	42.9 ± 9.7	44.2 ± 11.3	NS
ODI3%	19.2 ± 4.9	36.2 ± 10.9	63.3 ± 9.4	<0.01**
VWFM group				
1	12 (80)	8 (36)	9 (43)	<0.05*
2	3 (20)	10 (45)	5 (24)	NS
3	0	4 (18)	7 (33)	<0.05*
VWF:Ag at 06:00 h %	98.5 ± 49.1	98.5 ± 55.7	111.3 ± 75.5	NS
ADAMTS13:AC at 06:00 h %	58.1 ± 20.2	55.2 ± 21.9	57.6 ± 25.6	NS
VWF:CB at 06:00 h U·mL ⁻¹	1.29 ± 0.39 (n=13)	1.23 ± 0.50 (n=19)	1.09 ± 0.38 (n=19)	NS
Pit/Ht at 06:00 h × 10 ⁹ ·L ⁻¹ ·% ⁻¹	0.526 ± 0.093 (n=10)	0.549 ± 0.138 (n=13)	0.561 ± 0.087 (n=8)	NS

Data are presented as mean ± SD or n (%), unless otherwise stated. M: males; F: females; ODI3%: oxygen desaturation index ≥ 3%; VWFM: von Willebrand factor multimer; VWF:Ag: von Willebrand factor antigen; ADAMTS13:AC: a disintegrin-like, metalloproteinase, and thrombospondin type 1 motifs 13 activity; Pit/Ht: platelet count to haematocrit ratio; NS: not significant. *: p < 0.05 between 15 ≤ AHI < 30 and 30 ≤ AHI < 60, AHI ≥ 60, **: p < 0.01 between all AHI groups, #: p < 0.05 between 15 ≤ AHI < 30 and AHI ≥ 60.

had AHI ≥ 30 and more predominantly with AHI ≥ 60. The incident for group 1 patients was lower in AHI groups of 30 ≤ AHI < 60 and AHI ≥ 60 than those of 15 ≤ AHI < 30 (p < 0.05). In contrast, the incident for group 3 was higher in AHI ≥ 60 than those of 15 ≤ AHI < 30 (p < 0.05). No significant relationship between AHI score and each parameter such as VWF, ADAMTS13, or platelet count was found.

DISCUSSION

Plasma VWF:Ag levels increase after the age of 40 yrs in normal individuals; by the age of 60 yrs they can have reached ~120–140% of the healthy normal baseline [26]. The mean age of OSA patients enrolled in this study was 44.7 yrs, whereas that of control subjects was 38.3 yrs. However, the plasma VWF:Ag levels collected at 06:00 h were significantly lower for OSA patients than for control subjects (table 1). In contrast, plasma ADAMTS13 activity decreases after the age of 40 yrs in normal individuals [27]. Among our study patients and controls, plasma ADAMTS13:AC was lower than in healthy controls aged between 20–40 yrs (p < 0.01), indicating that these two groups did not significantly differ (table 1).

Given the observed differences in VWF:Ag levels between OSA patients and control subjects, we analysed VWFM patterns chronologically at three time points: at 21:00 h and at 06:00 h either with or without overnight CPAP treatment. As expected, a majority of OSA patients (29 (50%) out of 58) had consistently normal VWFM patterns, categorised as group 1. Two smaller groups of patients had increased UL- and HMW-VWFM (18 (31%) out of 58) or decreased UL- and HMW-VWFM (11 (19%) out of 58) at 06:00 h; these were categorised as group 2 or group 3, respectively. The ratio of LMW-VWFM to total VWFM, termed the LMW ratio, is a determination of the relative amount of degraded VWFM; in our study population, the LMW ratio correlated significantly with the AHI.

The increased LMW ratio seen in OSA patients could arise from reduced production of VWF by vascular endothelial cells,

increased clearance of HMW-VWFM from the circulation, or consumption during thrombosis. However, *in vitro* studies have clearly shown that VWF expression by cultured vascular endothelial cells is increased under conditions of hypoxia; it is unlikely that patients with OSA, a condition of intermittent hypoxia, would exhibit decreased expression of VWF overnight [17]. Additionally, no differences were seen in the plasma ADAMTS13:AC in any group at any time-point, suggesting that enhanced proteolysis of HMW-VWFM was not occurring. Therefore, we hypothesised that the elevated LMW ratio seen in our OSA patients was likely to be due to an enhanced degradation or consumption of HMW-VWFM.

The cause of thrombotic complications in OSA patients might be multifactorial, but in this study we have clearly indicated that VWF appears to play an essential role in the thrombogenesis in a certain population categorised as group 3. Although the mechanism is not yet fully elucidated, the high VWFMs released upon hypoxia from vascular endothelial cells is a most plausible factor. Thus, severe OSA could be a risk factor for both arterial and venous thrombosis as described in the introduction.

To better understand whether some degree of thrombosis was occurring overnight in untreated OSA patients, we determined platelet counts in 31 out of 58 patients; we observed a significant decrease in platelet count between 21:00 h and 06:00 h. This decrease was associated with reductions in both the plasma VWF:Ag levels and HMW-VWFM in group 3. Quantitative analyses of VWFMs in group 3 showed that levels of HMW-VWFM increased significantly after CPAP treatment, compared with measurements taken at 06:00 h without CPAP. This is consistent with low-level consumption of UL- and HMW-VWFM by microvascular thrombus formation and/or platelet aggregation during sleep in OSA patients; CPAP therapy might reduce such consumption. However, no patients have developed overt clinical signs of thromboembolic complications; therefore, we prefer to use the term "pre-clinical platelet consumption"

to describe this phenomenon. This may represent a baseline pro-thrombotic state in OSA patients that can be corrected by CPAP therapy.

In this study, the chronological analyses have unanimously indicated that reduced large VWFMs in plasmas at dawn reflect the clinical severity of apnoea in OSA patients. The results obtained by VWF analysis were solid, but the procedure was time consuming and requires a high technical skill to perform. A reliable high-throughput method would be necessary for routine clinical use. In this regard, the assay for VWF:CB is a promising candidate for such a method, because HMW-VWF adheres to collagen with a higher binding affinity than IMW- or LMW-VWF. Our results indicated that VWF:CB at 06:00 h correlated well with VWF patterns, and was consistent with earlier assignment of subjects to groups 1–3. Thus, through this study we have provided the first convincing evidence that VWF at dawn in group 3 was impaired not only structurally but also functionally, presumably due to hypoxia-induced release and consumption of VWF. This process might also involve platelet aggregation and consumption, even though the patients were asymptomatic. Thus, large scale studies, together with chronological measurements of platelet counts and VWF:CB, would be the focus in the following studies.

SUPPORT STATEMENT

This study was partly supported by research grants to the Respiratory Failure Research Group and Coagulation Abnormalities Research Group from the Ministry of Health, Labour and Welfare and from the Ministry of Education, Culture, Sports, Science and Technology of Japan.

STATEMENT OF INTEREST

None declared.

ACKNOWLEDGEMENTS

We would like to thank K. Makinodan, A. Fukuoka, and M. Yamauchi (Second Dept of Internal Medicine, Nara Medical University, Nara, Japan) for collecting blood samples and A. Isonishi (Dept of Blood Transfusion Medicine, Nara Medical University) for her excellent technical assistance. We would also like to thank M. Uemura (Third Dept of Internal Medicine, Nara Medical University) for his critical reading of this manuscript.

REFERENCES

- Malhotra A, White DP. Obstructive sleep apnoea. *Lancet* 2002; 360: 237–245.
- Moore T, Rabben T, Wiklund U, et al. Sleep-disordered breathing in men with coronary artery disease. *Chest* 1996; 109: 659–663.
- Shahar E, Whitney CW, Redline S, et al. Sleep-disordered breathing and cardiovascular disease: cross-sectional results of the Sleep Heart Health Study. *Am J Respir Crit Care Med* 2001; 163: 19–25.
- Redline S, Yenokyan G, Gottlieb DJ, et al. Obstructive sleep apnea-hypopnea and incident stroke: the sleep heart health study. *Am J Respir Crit Care Med* 2010; 182: 269–277.
- Marin JM, Carrizo SJ, Vicente E, et al. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. *Lancet* 2005; 365: 1046–1053.
- Epstein MD, Segal LN, Ibrahim SM, et al. Snoring and risk of obstructive sleep apnea in patients with pulmonary embolism. *Sleep* 2010; 33: 1069–1074.
- Bosanquet JP, Bade BC, Zia MF, et al. Patients with venous thromboembolism appear to have higher prevalence of obstructive sleep apnea than the general population. *Clin Appl Thromb Hemost* 2011; 17: E119–E124.
- Ruggeri ZM, Von Willebrand factor, platelets and endothelial cell interactions. *J Thromb Haemost* 2003; 1: 1335–1342.
- Sadler JE, Moake JL, Miyata T, et al. Recent advances in thrombotic thrombocytopenic purpura. *Hematology Am Soc Hematol Educ Program*, 2004: 407–423.
- Moake JL, Rudy CK, Troll JH, et al. Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. *N Engl J Med* 1982; 307: 1432–1435.
- Levy GG, Nichols WC, Lian EC, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. *Nature* 2001; 413: 488–494.
- Thompson SG, Kienast J, Pyke SD, et al. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. *N Engl J Med* 1995; 332: 635–641.
- Chion CK, Doggen CJ, Crawley JT, et al. ADAMTS13 and von Willebrand factor and the risk of myocardial infarction in men. *Blood* 2007; 109: 1998–2000.
- Bongers TN, de Maat MP, van Goor ML, et al. High von Willebrand factor levels increase the risk of first ischemic stroke: influence of ADAMTS13, inflammation, and genetic variability. *Stroke* 2006; 37: 2672–2677.
- Kaikita K, Soejima K, Matsukawa M, et al. Reduced von Willebrand factor-cleaving protease (ADAMTS13) activity in acute myocardial infarction. *J Thromb Haemost* 2006; 4: 2490–2493.
- Wilkie ME, Stevens CR, Cunningham J, et al. Hypoxia-induced von Willebrand factor release is blocked by verapamil. *Miner Electrolyte Metab* 1992; 18: 141–144.
- Pinsky DJ, Naka Y, Liao H, et al. Hypoxia-induced exocytosis of endothelial cell Weibel-Palade bodies. A mechanism for rapid neutrophil recruitment after cardiac preservation. *J Clin Invest* 1996; 97: 493–500.
- von Känel R, Loredi JS, Ancoli-Israel S, et al. Association between sleep apnea severity and blood coagulability: treatment effects of nasal continuous positive airway pressure. *Sleep Breath* 2006; 10: 139–146.
- Robinson GV, Pepperell JC, Segal HC, et al. Circulating cardiovascular risk factors in obstructive sleep apnoea: data from randomised controlled trials. *Thorax* 2004; 59: 777–782.
- Bartlett A, Dormandy KM, Hawkey CM, et al. Factor-VIII-related antigen: measurement by enzyme immunoassay. *Br Med J* 1976; 1: 994–996.
- Matsumoto M, Kawaguchi S, Ishizashi H, et al. Platelets treated with ticlopidine are less reactive to unusually large von Willebrand factor multimers than are those treated with aspirin under high shear stress. *Pathophysiol Haemost Thromb* 2005; 34: 35–40.
- Ruggeri ZM, Zimmerman TS. Variant von Willebrand's disease: characterization of two subtypes by analysis of multimeric composition of factor VIII/von Willebrand factor in plasma and platelets. *J Clin Invest* 1980; 65: 1318–1325.
- Budde U, Schneppenheim R, Plendl H, et al. Luminographic detection of von Willebrand factor multimers in agarose gels and on nitrocellulose membranes. *Thromb Haemost* 1990; 63: 312–315.
- Veyradier A, Nishikubo T, Humbert M, et al. Improvement of von Willebrand factor proteolysis after prostacyclin infusion in severe pulmonary arterial hypertension. *Circulation* 2000; 102: 2460–2462.
- Kato S, Matsumoto M, Matsuyama T, et al. Novel monoclonal antibody-based enzyme immunoassay for determining plasma levels of ADAMTS13 activity. *Transfusion* 2006; 46: 1444–1452.
- Conlan MG, Folsom AR, Finch A, et al. Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study. *Thromb Haemost* 1993; 70: 380–385.
- Kokame K, Nobe Y, Kokubo Y, et al. FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. *Br J Haematol* 2005; 129: 93–100.

Acquired Idiopathic ADAMTS13 Activity Deficient Thrombotic Thrombocytopenic Purpura in a Population from Japan

Masanori Matsumoto¹, Charles L. Bennett², Ayami Isonishi¹, Zaina Qureshi², Yuji Hori¹, Masaki Hayakawa¹, Yoko Yoshida¹, Hideo Yagi¹, Yoshihiro Fujimura^{1*}

¹ Department of Blood Transfusion Medicine, Nara Medical University, Kashihara, Japan, ² South Carolina Center of Economic Excellence for Medication Safety and Efficacy and the Southern Network on Adverse Reactions (SONAR), South Carolina College of Pharmacy, University of South Carolina, Columbia, South Carolina, United States of America

Abstract

Thrombotic thrombocytopenic purpura (TTP) is a type of thrombotic microangiopathy (TMA). Studies report that the majority of TTP patients present with a deficiency of ADAMTS13 activity. In a database of TMA patients in Japan identified between 1998 and 2008, 186 patients with first onset of acquired idiopathic (ai) ADAMTS13-deficient TTP (ADAMTS13 activity <5%) were diagnosed. The median age of onset of TTP in this group of patients was 54 years, 54.8% were female, 75.8% had renal involvement, 79.0% had neurologic symptoms, and 97.8% had detectable inhibitors to ADAMTS13 activity. Younger patients were less likely to present with renal or neurologic dysfunction ($p < 0.01$), while older patients were more likely to die during the TTP hospitalization ($p < 0.05$). Findings from this cohort in Japan differ from those reported previously from the United States, Europe, and Korea with respect to age at onset (two decades younger in the other cohort) and gender composition (60% to 100% female in the other cohort). We conclude that in one of the largest cohorts of ai-TTP with severe deficiency of ADAMTS13 activity reported to date, demographic characteristics differ in Japanese patients relative to those reported from a large Caucasian registry from Western societies. Additional studies exploring these findings are needed.

Citation: Matsumoto M, Bennett CL, Isonishi A, Qureshi Z, Hori Y, et al. (2012) Acquired Idiopathic ADAMTS13 Activity Deficient Thrombotic Thrombocytopenic Purpura in a Population from Japan. PLoS ONE 7(3): e33029. doi:10.1371/journal.pone.0033029

Editor: Pieter H. Reitsma, Leiden University Medical Center, The Netherlands

Received: July 1, 2011; **Accepted:** February 9, 2012; **Published:** March 12, 2012

Copyright: © 2012 Matsumoto et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by research grants from the Ministry of Education, Culture, Sports, Science and Technology of Japan and from the Ministry of Health, Labor, and Welfare of Japan. Y.F. is a member of clinical advisory boards for Baxter BioScience, no other funders had a role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have read the journal's policy and have the following conflicts: Y.F. is a member of clinical advisory boards for Baxter BioScience. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.

* E-mail: malon@narmed-u.ac.jp

Introduction

Thrombotic thrombocytopenic purpura (TTP) is a life-threatening generalized disorder and originally defined by classic "pentad"; thrombocytopenia, microangiopathic hemolytic anemia (MAHA), renal impairment, neurological symptoms, and fever [1]. In 1998, two studies identified deficiency of plasma ADAMTS13 (a disintegrin-like and metalloprotease with thrombospondin type 1 motifs 13) activity (ADAMTS13:AC) among persons with TTP [2,3]. ADAMTS13 cleaves the peptide bond between Thy1605 and Met1606 in the A2 domain of von Willebrand factor (VWF) subunit. VWF is synthesized in vascular endothelial cells and megakaryocytes. Vascular endothelial cell-derived VWF is released into the plasma as unusually large VWF multimers (UL-VWFMs). UL-VWFMs are degraded into smaller size VWF multimers by ADAMTS13. Severe deficiency of ADAMTS13:AC, either congenital or acquired, results in accumulation of UL-VWFMs and formation of platelet thrombi in the microvasculatures. In congenital TTP (Upshaw-Schulman syndrome), ADAMTS13 deficiency is caused by mutations in the ADAMTS13 gene [4]. In contrast, acquired TTP is frequently caused by inhibitory autoantibodies against ADAMTS13 [2,3].

Most acquired TTP patients have IgG antibodies. In rare cases, IgA and/or IgM antibodies are associated with IgG antibodies [5,6]. Patients with severe ADAMTS13:AC deficiency present with a lower platelet count and a significantly increased risk of TTP relapse [7–10]. Only a few small cohort studies of acquired idiopathic TTP patients characterized by severe ADAMTS13:AC deficiency have been reported previously. These studies characterize TTP with a predilection for the young and female, high rates of renal and central nervous system (CNS) involvement, and a 15% to 20% mortality. The largest cohort of acquired idiopathic (ai)-severely ADAMTS13-deficient TTP patients previously reported is from the Oklahoma TTP Registry ($n = 60$) [10]. In this study we systematically analyzed the clinical and laboratory features of a large cohort of Japanese patients with acquired idiopathic TTP and who also have severe ADAMTS13:AC deficiency.

Results

The number of ai-TTP patients fit the above inclusion criteria and retained for the study was 186. Of these, 31 (16.7%) were diagnosed between 1998 and 2001, 84 (45.2%) between 2002 and

2005, and 71 (38.2%) since 2006. This included individuals who did not experience any exposure to drugs that cause TTP or TMA, organ transplantation, stem cell transplantation, immunologic disease and also did not have a prior history of TTP. The age distribution of disease onset ranged from 8 months to 87 years old, with peak incidence occurring at age 60 (Figure 1, upper panel). Patients under 20 years accounted for 9.1% (17/186) of this subgroup, while patients over age 80 years accounted for 3.8% (7/186). Females accounted for 54.8%. Laboratory studies revealed that 100% of these patients were thrombocytopenic, 75.8% had renal involvement, and 79.0% had neurologic involvement. Overall, 16.1% died from TTP. ADAMTS13 inhibitors (≥ 0.5 BU/ml) were identified in 182 patients (97.8%). As shown in Figure 1 lower panel, 8.1% of these patients had inhibitor titers of $0.5 \sim < 1.0$ BU/ml, 35.5% had titers of $1.0 \sim < 2.0$, 33.3% had inhibitor titers of $2.0 \sim < 5.0$, 12.9% had inhibitor titers of $5.0 \sim < 10$, and 8.1% had inhibitor titers of ≥ 10 BU/ml. We found four ai-TTP patients without ADAMTS13 inhibitor (< 0.5 BU/ml), whose ADAMTS13:AC, however, was normalized after remission. Therefore, these patients were included in this study.

The ai-TTP patients were evaluated according to the age at diagnosis (Table 1); Group 1 (< 20 years old: $n = 17$), Group 2 ($20 \sim < 40$ years old: $n = 36$), Group 3 ($40 \sim < 60$ years old: $n = 63$), and Group 4 (60 years old \sim : $n = 70$). Rates of renal and neurologic dysfunction at the time of TTP presentation were lowest in the youngest age-subgroup (52.9% versus 72.2% to 81.0% for renal involvement; and 47.0% versus 69.4% to 88.6% for neurologic involvement; $p < 0.01$) while in-patient mortality was highest among the oldest sub-group (28.6% versus 5.9% to 11.1%, $p < 0.01$). Overall, females accounted for 54.8% of the patients (with rates of female gender ranging from 45.7% to 69.4% in each of the four age-groups).

Discussion

We evaluated 186 patients with initial onset of severely deficient ADAMTS13:AC levels TTP in Japan, representing the largest cohort of ai-TTP patients with ADAMTS13:AC deficiency reported from Japan. These individuals had presented with TMA-findings to medical centers throughout Japan over a ten-year period. In interpreting our findings, several factors should be considered.

These individuals accounted for 71.5% of 260 patients with a first episode of ai-TTP, who were diagnosed in our registry. This rate is similar to that reported previously for smaller cohorts of TTP patients from Europe, the United States, Canada, the United Kingdom, and Korea [7–13].

Sociodemographic characteristics of these TTP patients were compared to those reported from cohorts in Oklahoma, Saint Louis, France, and Korea [7–10,13] (Table 2). The median age of TTP patients with severely deficient ADAMTS13:AC levels reported from the other cohorts except for Saint Louis is 15 to 20 years less than that reported for our cohort. Also, females accounted for 53.8% of patients in our cohort versus 60% to 100% in other cohorts. Since additional information on predisposing factors for TTP are not known currently, it is not possible to identify factors accounting for age- and gender-related differences noted between TTP patients in Japan with severe ADAMTS13-deficiency versus those reported from other geographic regions.

Age-related differences in rates of neurologic and renal involvement among TTP patients who had severely deficient ADAMTS13:AC levels have not been reported previously. We found lower rates of renal and neurologic dysfunction amongst the youngest TTP patients, and the highest short-term mortality rates among the oldest TTP patients. While our study evaluated 186 patients with initial onset of severe ADAMTS13:AC activity




Figure 1. Age distribution and ADAMTS13 inhibitor levels in acquired idiopathic (ai-) TTP with severe deficiency of ADAMTS13 activity. Upper panel shows the age distribution of 186 patients with severe deficiency of ADAMTS13 activity under 5%. We found wide range of the age at TTP bouts from 8 months old to 87 years old. The highest incident peak was found around 60 years old. Lower panel shows the distribution of ADAMTS13 inhibitors in 186 ai-TTP patients with severe deficiency of ADAMTS13 activity. We found ADAMTS13 inhibitors (≥ 0.5 BU/ml) in 182 patients (97.8%). High titer inhibitors ≥ 2.0 BU/ml was seen in 101 patients (54.3%).
doi:10.1371/journal.pone.0033029.g001

deficiency, the other cohorts included smaller number of patients with idiopathic TTP and severe ADAMTS13:AC deficiency [7–9,11–13]. These age-related differences in clinical findings may account in part for higher short-term mortality rates observed among older patients with TTP in our cohort, as well as in the cohort reported from Canada [14].

Fourth, inhibitory autoantibodies against ADAMTS13 were identified in 97.8% of patients with ADAMTS13:AC deficient TTP. Other cohorts identify inhibitory antibodies in 44% to 94% of TTP patients with severely deficient ADAMTS13:AC levels [7–13]. These findings reflect variable sensitivity and specificity of ADAMTS13:AC inhibitor tests. In our study, ADAMTS13 inhibitor levels of 5 or more BU/ml were identified in 21.0% of TTP patients with severely deficient ADAMTS13:AC levels and inhibitor levels of 10 or more BU/ml were noted in 8.1%. These TTP patients with severely deficient ADAMTS13:AC activity levels and high titer inhibitors to ADAMTS13 might represent a subgroup of TTP patients for whom rituximab therapy might be particularly beneficial [12]. In general, the role of IgG antibody levels in ai-TTP is felt to be controversial. Some investigators report an association of higher titers with increased mortality, refractoriness, and more severe presentation [10,15], while others have not found similar results [7,16].

Our study has the limitation that follow-up ended at the time of hospital discharge, which prevented us from reporting on relapse rates and long-term survival rates. A second limitation is that TTP patients who were not severely deficient in ADAMTS13:AC levels were not included in this study. As noted by others, this is a heterogeneous group of patients—many of whom have diseases other than TTP. Another limitation is that while our laboratory is a distinguished referral center for TMAs in Japan, it is not mandatory that information on all TMA patients is sent to our laboratory, and hence a number of patients with TMAs in Japan are not entered into our database. A final limitation is that cohorts in two of the five comparison studies (from Korea and Oklahoma) included a minority of individuals with TTP who did not have primary idiopathic TTP [10,13].

In summary, findings from this cohort of TTP patients in Japan with severe ADAMTS13:AC deficiency parallel those reported from TTP cohorts in Europe, the United States, Canada, the United Kingdom, and Korea in several ways, but also provide insights that have not been reported previously [7–14]. Novel findings in this cohort include females accounting for only 54.8% of incident cases, a higher median age at TTP onset of 54 years, and higher mortality rates amongst patients who were older than 60 years of age. Given the rarity of TTP in the general population, aggregation of findings from various TTP cohorts reported from Japan, Korea, France, England, Saint Louis, Oklahoma, and Canada might yield important findings that single registries would be unable to identify. A particularly important finding might be development and validation of a multivariate model predictive of mortality of persons with incident TTP characterized by severe ADAMTS13:AC deficiency.

Methods

Since 1998, our laboratory has been a nationwide referral center within Japan for TMAs, with 919 patients having been registered in this database [17]. During the first years of the study, samples from all TMA patients were evaluated by our referral center. In recent years, commercial laboratories now provide access to ADAMTS13:AC evaluation and some centers therefore do not submit samples to our group. We are not able to ascertain which centers are sending samples to commercial vendors at this time. Of these 919

patients, 186 patients were diagnosed with first onset of ai-TTP characterized by severe deficiency of ADAMTS13:AC (<5%) and no prior history of TTP. Exclusion criteria were exposure to drugs that cause TTP or TMA, organ transplantation, stem cell transplantation, immunologic disease, or ADAMTS13:AC levels 5% and more. All patients gave written informed consent to participate in this study. The study protocol was approved by the Ethics Committee of Nara Medical University Hospital.

Diagnostic criteria

The classic pentad for TTP was defined as follows (i) microangiopathic hemolytic anemia (hemoglobin ≤ 12 g/dL), Coombs test negative, undetectable serum haptoglobin (<10 mg/dL), more than 2 fragmented red cells (schistocytes) in a microscopic field with a magnification of 100, and concurrent increased serum lactate dehydrogenase (LDH) above institutional baseline, (ii) thrombocytopenia (platelet count $\leq 100 \times 10^9/L$), (iii) fever $\geq 37^\circ C$, (iv) CNS involvement: ranging from headache to coma, including neurological dysfunction, convulsion, clouding of consciousness, and (v) renal involvement (including abnormal urinalysis in addition to elevation of serum creatinine level). Patients were excluded if they reported a prior episode of ai-severely ADAMTS13-deficient TTP ($n = 18$ patients).

Blood Sampling

Before therapeutic approaches were initiated, whole blood samples (~5 ml) were phlebotomized from each patient and placed into plastic tubes containing 1/10 volume of 3.8% sodium citrate. The plasma was separated by centrifugation at 3000 g for 15 min at $4^\circ C$, kept in aliquots at $-80^\circ C$ until testing, and sent to our laboratory with clinical information.

Assays of plasma ADAMTS13:AC and ADAMTS13:INH

Until March 2005, ADAMTS13:AC was determined by classic von Willebrand factor multimer (VWFm) assay with a detection limit of 3% of the normal control [18,19]. Thereafter, a chromogenic ADAMTS13-act-ELISA [20] with a detection limit of 0.5% of the normal control was developed, and replaced the VWFm assay. Thus, most of the plasma samples stored at $-80^\circ C$ were re-evaluated with chromogenic act-ELISA, but 22 samples were unable to evaluate by the new method, because of a short of the stored sample volume. Basically, however, the results obtained by both the assays had a high correlation ($r = 0.99$) [20]. Thus, the results determined by VWFm alone were also included in this study. Further, to compare the results from other investigators and potentially with different assay methods for ADAMTS13:AC, we here categorized plasma levels of ADAMTS13:AC of severe (<5%), moderate (5%~<25%), mild (25%~<50%) deficiency and normal ($\geq 50\%$) of ADAMTS13:AC. Plasma ADAMTS13:INH titers were analyzed either by classic VWFm assay or chromogenic ADAMTS13-act-ELISA using heat-inactivated plasmas at $56^\circ C$ for 30 min. Briefly, the tested samples were mixed with an equal volume of the normal plasmas and incubated at $37^\circ C$ for 2 hours. After incubation, the residual ADAMTS13:AC was measured. One Bethesda unit (BU) is defined as the amount necessary to reduce ADAMTS13:AC to 50% of control levels according to the Bethesda method, which was originally developed for the measurement of factor VIII inhibitor [21]. Titers ≥ 0.5 BU/ml were classified as inhibitor-positive.

Statistical analysis

All continuous variables were reported as median values (25, 75 percentile). Comparisons between two patient groups (severe

Table 1. Clinical features in ai-TTP patients with severe deficiency of ADAMTS13:AC.

	All patients	Groups according to age				Overall p
		1	2	3	4	
Age (years)	54 (37, 65)	<20	20~<40	40~<60	60~	
	Median (25, 75 percentile)					
Patient Number	186	17	36	63	70	
Female (%)	54.8	52.9	69.4	57.1	45.7	NS
"Pentad"						
(1) Platelet count ($\times 10^9/L$), Median (25, 75 percentile)	10 (7, 16)	9 (7, 12)	10 (7, 20)	10 (6, 18)	10 (8, 15)	NS
(2) Hemoglobin (g/dL), Median (25, 75 percentile)	7.3 (6.1, 8.7)	7.4 (5.4, 8.7)	6.7 (5.9, 7.8)	7.1 (6.0, 8.8)	7.8 (6.6, 8.8)	NS
(3) Renal involvement (%)	75.8	52.9	72.2	81.0	78.5	NS
Serum creatinine (mg/dL), Median (25, 75 percentile)	0.9 (0.7, 1.3)	0.58 (0.31, 0.80)	0.86 (0.70, 1.16)	0.95 (0.80, 1.50)	1.00 (0.80, 1.40)	<0.01 ^a
Blood urea nitrogen (mg/dL), Median (25, 75 percentile)	24 (17, 37)	15 (12, 23)	19 (14, 26)	27 (17, 41)	27 (21, 43)	<0.01 ^b
(4) CNS involvement (%)	79.0	47.0	69.4	82.5	88.6	<0.01 ^c
(5) Fever ($\geq 37.0^\circ C$) (%)	71.5	76.5	63.9	69.8	75.7	NS
Mortality in the current episode of TTP bouts (%)	16.1	5.9	5.6	11.1	28.6	<0.05 ^d

NS: not significant difference (≥ 0.05).

Overall p values were calculated using the Kruskal-Wallis H tests or chi-square tests with Yates' correction for 2×4 tables.

Significant differences between 4 groups (overall $p < 0.05$) were further analyzed by Mann-Whitney U-test or chi-square test.

^a $p < 0.01$ between Group 1 and Groups 2, 3, 4.

^b $p < 0.01$ between Group 1 and Groups 3, 4, and between Group 2 and Groups 3, 4.

^c $p < 0.01$ between Group 1 and Groups 3, 4.

^d $p < 0.05$ between Group 2 and Group 4.

doi:10.1371/journal.pone.0033029.t001

Table 2. Comparison of our findings with those reported from Europe, Asia, and the United States for acquired idiopathic TTP patients with severely deficient ADAMTS13:AC levels.

	This study (n = 186)	Vesely et al ⁷ (n = 16)	Zheng et al ⁸ (n = 16)	Coppo et al ⁹ (n = 31)	Kremer-Hovinga et al ¹⁰ (n = 60)	Jang et al ¹³ (n = 20)
Geographic region	Japan	Oklahoma (USA)	Saint Louis (USA)	France	Oklahoma (USA)	Korea
Ethnicity/race	Japanese 100%	White 50%, African-American 50%	White 32%, African-American 68%	White 52%, Afro-Caribbean 48%	African-American 35%	Korean 100%
Idiopathic etiology	100%	100%	100%	100%	77%	70%
Prior TMA	0%	0%	38%	13%	0%	ND
ADAMTS13:AC	<5%	<5%	<5%	<5%	<10%	<10%
ADAMTS13:INH	98%	94%	44%	55%	83%	ND
Age (years)	54 (8 m–87)	39 (19–71)	51 (21–79)	36 (19–67)	41 (9–72)	40.5 (mean)
% female	55	75	100	65	82	60
Platelets ($10^9/ul$)	10 (1–88)	11(4–27)	17 (6–47)	12 (2–69)	11 (2–101)	24 (mean)
Hb (g/dl)	7.3 (4.3–11.9)	ND	ND	7.3 (4.6–13.7)	ND	7.7 (mean)
Ht (%)	ND	21 (15–30)	25 (13–33)	ND	21 (13–33)	ND
Creatinine (mg/dl)	0.9 (0.7–10.7)	1.2(0.9–5.5)	1.1 (0.7–3.1)	1.1 (0.67–5.2)	1.6 (0.7–6.6)	1.6 (mean)
BUN (mg/dl)	23.4 (2.5–154)	ND	ND	ND	ND	ND
Fever (%)	72	ND	31	36	ND	70
CNS involvement (%)	79	50	56	74	50	25
% Survival	84	81	81	87	78	81

ND: no data.

Median (minimum-maximum).

doi:10.1371/journal.pone.0033029.t002

deficiency and detectable ADAMTS13 activity) were tested for statistical significance using the Mann-Whitney U-tests or chi-square tests. Comparisons between 4 patients groups (under 20 years old, 20 to under 40 years old, 40 to under 60 years old, and over 60 years old) were calculated using the Kruskal-Wallis H tests or chi-square tests with Yates' correction for 2×4 tables. Significant differences between 4 groups (overall $p < 0.05$) were further analyzed by Mann-Whitney U-tests or chi-square tests. Correlation between ADAMTS13:AC and :INH was analyzed by

Spearman's correlation. A two-tailed P value less than 0.05 was considered to be significant.

Author Contributions

Conceived and designed the experiments: YF. Performed the experiments: AI YH MH YY HY. Analyzed the data: MM. Wrote the paper: MM CB YF ZQ.

References

1. Amorosi EL, Ultmann JE (1966) Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature. *Medicine* 45: 139–159.
2. Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, et al. (1998) von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. *N Engl J Med* 339: 1578–1584.
3. Tsai HM, Lian EC (1998) Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. *N Engl J Med* 339: 1585–1594.
4. Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, et al. (2001) Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. *Nature* 413: 488–494.
5. Scheifflinger F, Knobl P, Trattner B, Trattner B, Plaimauer B, et al. (2003) Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura. *Blood* 102: 3241–3243.
6. Ferrari S, Scheifflinger F, Rieger M, Mudde G, Wolf M, et al. (2007) Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity. *Blood* 109: 2815–2822.
7. Vesely SK, George JN, Lämmle B, Studt JD, Alberio L, et al. (2003) ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. *Blood* 102: 60–68.
8. Zheng XL, Kaufman RM, Goodnough LT, Sadler JE (2004) Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. *Blood* 103: 4043–4049.
9. Coppo P, Bengoufa D, Veyradier A, Wolf M, Bussel A, et al. (2004) Severe ADAMTS13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement. *Medicine (Baltimore)* 83: 233–244.
10. Kremer-Hovinga JA, Vesely SK, Terrell DR, Lämmle B, George JN (2010) Survival and relapse in patients with thrombotic thrombocytopenic purpura. *Blood* 115: 1500–1511.
11. Veyradier A, Obert B, Houllier A, Meyer D, Girma JP (2001) Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases. *Blood* 98: 1765–1772.
12. Scully M, Yarranton H, Liesner R, Cavenagh J, Hunt B, et al. (2008) Regional UK TTP registry: correlation with laboratory ADAMTS 13 analysis and clinical features. *Br J Haematol* 142: 819–826.
13. Jang MJ, Chong SY, Kim IH, Kim JH, Jung CW, et al. (2011) Clinical features of severe acquired ADAMTS13 deficiency in thrombotic thrombocytopenic purpura: the Korean TTP registry experience. *Int J Hematol* 93: 163–169.
14. Wylie BF, Garg AX, Macnab J, Rock GA, Clark WF, et al. (2006) Thrombotic thrombocytopenic purpura/haemolytic uraemic syndrome: a new index predicting response to plasma exchange. *Br J Haematol* 132: 204–209.
15. Tsai HM (2000) High titers of inhibitors of von Willebrand factor-cleaving metalloproteinase in a fatal case of acute thrombotic thrombocytopenic purpura. *Am J Hematol* 65: 251–255.
16. Bohm M, Betz C, Miesbach W, Krause M, von Auer C, et al. (2005) The course of ADAMTS-13 activity and inhibitor titre in the treatment of thrombotic thrombocytopenic purpura with plasma exchange and vincristine. *Br J Haematol* 129: 644–652.
17. Fujimura Y, Matsumoto M (2009) Registry of 919 patients with thrombotic microangiopathies across Japan: database of Nara Medical University during 1998–2008. *Intern Med* 49: 7–15.
18. Furlan M, Robles R, Lämmle B (1996) Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. *Blood* 87: 4223–4234.
19. Kinoshita S, Yoshioka A, Park YD, Ishizashi H, Konno M, et al. (2001) Upshaw-Schulman syndrome revisited: a concept of congenital thrombotic thrombocytopenic purpura. *Int J Hematol* 74: 101–108.
20. Kato S, Matsumoto M, Matsuyama T, Isonishi A, Hiura H, et al. (2006) Novel monoclonal antibody-based enzyme immunoassay for determining plasma levels of ADAMTS13 activity. *Transfusion* 46: 1444–1452.
21. Kasper CK, Aledort L, Aronson D, Counts R, Edson JR, et al. (1975) Proceedings: A more uniform measurement of factor VIII inhibitors. *Thromb Diath Haemorrh* 34: 612.

